Citation: | Li Haibo, Fu Hongyuan, Lu Tongyu, et al. Summary of important research on liver transplantation in 2017[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 41-50,82. doi: 10.3969/j.issn.1674-7445.2018.01.006 |
[1] |
RAKHRA SS, OPDAM HI, GLADKIS L, et al. Untapped potential in Australian hospitals for organ donation after circulatory death[J]. Med J Aust, 2017, 207(7): 294-301. DOI: 10.5694/mja16.01405.
|
[2] |
CROOME KP, LEE DD, KEAVENY AP, et al. Improving national results in liver transplantation using grafts from donation after cardiac death donors[J]. Transplantation, 2016, 100(12): 2640-2647. DOI: 10.1097/tp.0000000000001483.
|
[3] |
CROOME KP, LEE DD, PERRY DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort[J]. Liver Transpl, 2017, 23(3): 342-351. DOI: 10.1002/lt.24713.
|
[4] |
TRIVEDI PJ, SCALERA I, SLANEY E, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis[J]. J Hepatol, 2017, 67(5): 957-965. DOI: 10.1016/j.jhep.2017.06.027.
|
[5] |
SCHLEGEL A, LINECKER M, KRON P, et al. Risk assessment in high-and low-MELD liver transplantation[J]. Am J Transplant, 2017, 17(4): 1050-1063. DOI: 10.1111/ajt.14065.
|
[6] |
BOHORQUEZ H, SEAL JB, COHEN AJ, et al. Safety and outcomes in 100 consecutive donation after circulatory death liver transplants using a protocol that includes thrombolytic therapy[J]. Am J Transplant, 2017, 17(8): 2155-2164. DOI: 10.1111/ajt.14261.
|
[7] |
DE CARLIS R, DI SANDRO S, LAUTERIO A, et al. Successful donation after cardiac death liver transplants with prolonged warm ischemia time using normothermic regional perfusion[J]. Liver Transpl, 2017, 23(2): 166-173. DOI: 10.1002/lt.24666.
|
[8] |
WATSON CJE, KOSMOLIAPTSIS V, RANDLE LV, et al. Normothermic perfusion in the assessment and preservation of declined livers before transplantation: hyperoxia and vasoplegia-important lessons from the first 12 cases[J]. Transplantation, 2017, 101(5): 1084-1098. DOI: 10.1097/tp.0000000000001661.
|
[9] |
BRAL M, GALA-LOPEZ B, BIGAM D, et al. Preliminary single-center Canadian experience of human normothermic ex vivo liver perfusion: results of a clinical trial[J]. Am J Transplant, 2017, 17(4): 1071-1080.DOI: 10.1111/ajt.1428110.1111/ajt.14049.
|
[10] |
CEPEDA-FRANCO C, BERNAL-BELLIDO C, BARRERA-PULIDO L, et al. Survival outcomes in liver transplantation with elderly donors: analysis of Andalusian Transplant Register[J]. Transplant Proc, 2016, 48(9): 2983-2986. DOI: 10.1016/j.transproceed.2016.09.026.
|
[11] |
SCHLEGEL A, SCALERA I, THAMARA M, et al. Impact of donor age in donation after cardiac death liver transplantation: is the cut-off "60" still of relevance?[J]. Liver Transpl, 2017, DOI: 10.1002/lt.24865[Epub ahead of print].
|
[12] |
BIANCOFIORE G, BINDI M, GHINOLFI D, et al. Octogenarian donors in liver transplantation grant an equivalent perioperative course to ideal young donors[J]. Dig Liver Dis, 2017, 49(6): 676-682. DOI: 10.1016/j.dld.2017.01.149.
|
[13] |
KNAAK M, GOLDARACENA N, DOYLE A, et al. Donor BMI >30 is not a contraindication for live liver donation[J]. Am J Transplant, 2017, 17(3): 754-760. DOI: 10.1111/ajt.14019.
|
[14] |
COMPAGNON P, LEVESQUE E, HENTATI H, et al. An oxygenated and transportable machine perfusion system fully rescues liver grafts exposed to lethal ischemic damage in a pig model of DCD liver transplantation[J]. Transplantation, 2017, 101(7): e205-e213. DOI: 10.1097/tp.0000000000001764.
|
[15] |
KRON P, SCHLEGEL A, MANCINA L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans[J]. J Hepatol, 2017, DOI: 10.1016/j.jhep.2017.08.028[Epub ahead of print].
|
[16] |
HE X, JI F, ZHANG Z, et al. Combined liver-kidney perfusion enhances protective effects of normothermic perfusion on livers grafts from donation after cardiac death[J]. Liver Transpl, 2018, 24(1): 67-79. DOI: 10.1002/lt.24954.
|
[17] |
LAING R, BHOGAL RH, WALLACE LW, et al. The use of an acellular oxygen carrier in a human liver model of normothermic machine perfusion[J]. Transplantation, 2017, 101(11): 2746-2756. DOI: 10.1097/tp.0000000000001821.
|
[18] |
GIORGAKIS E, TEDESCHI M, BONACCORSI-RIANI E, et al. The effect of recipient body mass index and its extremes on survival and graft vascular and biliary complications after liver transplantation: a single center retrospective study[J]. Ann Transplant, 2017, 22: 611-621. DOI: 10.12659/AOT.903475.
|
[19] |
AZZAM AZ, TANAKA K. Biliary complications after living donor liver transplantation: a retrospective analysis of the Kyoto experience 1999-2004[J]. Indian J Gastroenterol, 2017, 36(4): 296-304. DOI: 10.1007/s12664-017-0771-3.
|
[20] |
PARK TY, LEE SK, NAM K, et al. Spontaneous hemobilia after liver transplantation: frequency, risk factors, and outcome of endoscopic management[J]. J Gastroenterol Hepatol, 2017, 32(3): 583-588. DOI: 10.1111/jgh.13497.
|
[21] |
APARICIO D, OTOCH JP, MONTERO EFS, et al. Endoscopic approach for management of biliary strictures in liver transplant recipients: a systematic review and Meta-analysis[J]. United European Gastroenterol J, 2017, 5(6): 827-845. DOI: 10.1177/2050640616681909.
|
[22] |
FUJIKI M, HASHIMOTO K, PALAIOS E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients[J]. Surgery, 2017, 162(5): 1101-1111. DOI: 10.1016/j.surg.2017.07.012.
|
[23] |
INCE V, ERSAN V, KARAKAS S, et al. Does preoperative transarterial chemoembolization for hepatocellular carcinoma increase the incidence of hepatic artery thrombosis after living-donor liver transplant?[J]. Exp Clin Transplant, 2017, 15(Suppl 2): 21-24. DOI: 10.6002/ect.TOND16.L7.
|
[24] |
HERRERO A, SOUCHE R, JOLY E, et al. Early hepatic artery thrombosis after liver transplantation: what is the impact of the arterial reconstruction type?[J]. World J Surg, 2017, 41(8): 2101-2110. DOI: 10.1007/s00268-017-3989-4.
|
[25] |
LI Q, WANG Y, MA T, et al. Impact of cigarette smoking on early complications after liver transplantation:a single-center experience and a Meta-analysis[J]. PLoS One, 2017, 12(5): e0178570. DOI: 10.1371/journal.pone.0178570.
|
[26] |
ROCCARO GA, GOLDBERG DS, HWANG WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Am J Transplantation, 2018, 18(1): 207-215. DOI: 10.1111/ajt.14401.
|
[27] |
LEE IJ, KIM SH, LEE SD, et al. Feasibility and midterm results of endovascular treatment of hepatic artery occlusion within 24 hours after living-donor liver transplantation[J]. J Vasc Interv Radiol, 2017, 28(2): 269-275. DOI: 10.1016/j.jvir.2016.06.029.
|
[28] |
YANG L, XIN EY, LIAO B, et al. Development and validation of a nomogram for predicting incidence of early allograft dysfunction following liver transplantation[J]. Transplant Proc, 2017, 49(6): 1357-1363. DOI: 10.1016/j.transproceed.2017.03.083.
|
[29] |
NACIF LS, PINHEIRO RS, DE ARRUDA PÉCORA RA, et al. Re-transplantation, higher creatinine levels in hepatitis C virus patients, and donor age are predictors of mortality in long-term analysis of late acute rejection in liver transplantation[J]. Ann Transplant, 2017, 22: 9-16. DOI: 10.12659/AOT.901010.
|
[30] |
SHAKED A, CHANG BL, BARNES MR, et al. An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection[J]. Hepatology, 2017, 65(1): 269-280. DOI: 10.1002/hep.28786.
|
[31] |
SAN SEGUNDO D, RUIZ P, IRURE J, et al. Serum levels of interleukin-34 during acute rejection in liver transplantation[J]. Transplant Proc, 2016, 48(9): 2977-2979. DOI: 10.1016/j.transproceed.2016.08.038.
|
[32] |
DETRY O, VANDERMEULEN M, DELBOUILLE MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase Ⅰ-Ⅱ, open-label, clinical study[J]. J Hepatol, 2017, 67(1): 47-55. DOI: 10.1016/j.jhep.2017.03.001.
|
[33] |
ABDELHAMID NM, CHEN YC, WANG YC, et al. Pre-transplantation immune cell distribution and early post-transplant fungal infection are the main risk factors of liver transplantation recipients in lower model of end-stage liver disease[J]. Transplant Proc, 2017, 49(1): 92-97. DOI: 10.1016/j.transproceed.2016.11.014.
|
[34] |
MALLET V, HAMED K, SCHWARZINGER M. Prognosis of patients with chronic hepatitis B in France (2008-2013): a nationwide, observational and hospital-based study[J]. J Hepatol, 2017, 66(3): 514-520.DOI: 10.1016/j.jhep.2016.10.031.
|
[35] |
WARREN-GASH C, CHILDS K, THORNTON A, et al. Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study[J]. Infection, 2017, 45(2): 215-220. DOI: 10.1007/s15010-016-0976-x.
|
[36] |
HUI Y, XIANGLI C, XIN W, et al. Clinical outcomes with antiviral prophylaxis or preemptive therapy for cytomegalovirus disease after liver transplantation: a systematic review and Meta-analysis[J]. J Pharm Pharm Sci, 2017, 20:15-27. DOI: 10.18433/j3rc90.
|
[37] |
BUTIN S, GRIFFOUL I, ESPITALIER F, et al. High incidence of vertebral osteoporotic fracture within the first year after liver transplantation[J]. Clin Exp Rheumatol, 2017, 35(6): 913-918. http://www.clinexprheumatol.org/abstract.asp?a=11110
|
[38] |
ALLARD MA, LOPES F, FROSIO F, et al. Extreme large-for-size syndrome after adult liver transplantation: a model for predicting a potentially lethal complication[J]. Liver Transpl, 2017, 23(10): 1294-1304. DOI: 10.1002/lt.24835.
|
[39] |
MEHTA N, HEIMBACH J, LEE D, et al. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time "sweet spot"[J]. Transplantation, 2017, 101(9): 2071-2078. DOI: 10.1097/tp.0000000000001752.
|
[40] |
PALMER WC, LEE D, BURNS J, et al. Liver transplantation for hepatocellular carcinoma: impact of wait time at a single center[J]. Ann Hepatol, 2017, 16(3): 402-411. DOI: 10.5604/16652681.1235483.
|
[41] |
AGOPIAN VG, HARLANDER-LOCKE MP, RUIZ RM, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3 601 patients from the us multicenter HCC transplant consortium[J]. Ann Surg, 2017, 266(3): 525-535. DOI: 10.1097/sla.0000000000002381.
|
[42] |
LEE MW, RAMAN SS, ASVADI NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis[J]. Hepatology, 2017, 65(6): 1979-1990. DOI: 10.1002/hep.29098.
|
[43] |
MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (retreat) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA oncol, 2017, 3(4): 493-500. DOI: 10.1001/jamaoncol.2016.5116.
|
[44] |
HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story[J]. Ann Surg, 265(3): 557-564. DOI: 10.1097/sla.0000000000001966.
|
[45] |
LAI Q, NICOLINI D, INOSTROZA NUNEZ M, et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation (train) score[J]. Ann Surg, 2016, 264(5): 787-796. DOI: 10.1097/sla.0000000000001881.
|
[46] |
BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/sla.0000000000001894.
|
[47] |
FUNG J, WONG T, CHOK K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatol, 2017, 66(4): 1036-1044. DOI: 10.1002/hep.29191.
|
[48] |
ULKU A, AKCAM AT, RENCUZOGULLARI A, et al. Effect of dosage and type of hepatitis B immunoglobulin on hepatitis antibody levels in liver transplant recipients[J]. Transplant Proc, 2017, 49(3): 575-579. DOI: 10.1016/j.transproceed.2017.01.024.
|
[49] |
STEPANOVA M, SAYINER M, DE AVILA L, et al. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor[J]. BMC Gastroenterol, 2016, 16(1): 137. DOI: 10.1186/s12876-016-0551-z.
|
[50] |
DHARANCY S, COILLY A, FOUGEROU-LEURENT C, et al. Direct-acting ANTIVIRAL agent-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study[J]. Am J Transplant, 2017, 17(11): 2869-2878. DOI: 10.1111/ajt.14490.
|
[51] |
HUSSAINI T, TURGEON RD, PARTOVI N, et al. Immunosuppression practices in liver transplantation: a survey of north American centers[J]. Exp Clin Transplant, 2017, DOI: 10.6002/ect.2017.0096[Epub ahead of print].
|
[52] |
AGUIAR D, MARTÍNEZ-URBISTONDO D, D'AVOLA D, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation[J]. Ann Transplant, 2017, 22: 141-147. DOI: 10.12659/AOT.901556.
|
[53] |
O'LEARY JG, CAI J, FREEMAN R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts[J]. Am J Transplant, 2016, 16(2):603-614. DOI: 10.1111/ajt.13476.
|
[54] |
O'LEARY JG, SMITH C, CAI J, et al. Chronic AMR in liver transplant: validation of the 1-year cAMR score's ability to determine long-term outcome[J]. Transplantation, 2017, 101(9): 2062-2070. DOI: 10.1097/tp.0000000000001802.
|
[55] |
KASAHARA M, UMESHITA K, SAKAMOTO S, et al. Living donor liver transplantation for biliary atresia: an analysis of 2085 cases in the registry of the Japanese liver transplantation society[J]. Am J Transplant, 2017, DOI: 10.1111/ajt.14489[Epub ahead of print].
|
[56] |
KITAJIMA T, SAKAMOTO S, SASAKI K, et al. Living donor liver transplantation for post-Kasai biliary atresia: analysis of pretransplant predictors of outcomes in infants[J]. Liver Transpl, 2017, 23(9): 1199-1209. DOI: 10.1002/lt.24796.
|
[57] |
ALEXOPOULOS SP, NEKRASOV V, CAO S, et al. Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia[J]. Liver Transpl, 2017, 23(2): 221-233. DOI: 10.1002/lt.24675.
|
[58] |
YANG H, ZHOU H, ZHUANG L, et al. Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice[J]. Liver Transpl, 2017, 23(1): 63-74. DOI: 10.1002/lt.24628.
|
[59] |
ZAOUALI MA, PANISELLO A, LOPEZ A, et al. GSK3β and VDAC involvement in er stress and apoptosis modulation during orthotopic liver transplantation[J]. Int J Mol Sci, 2017, 18(3): E591. DOI: 10.3390/ijms18030591.
|
[60] |
SELTEN JW, VERHOEVEN CJ, HEEDFELD V, et al. The release of microRNA-122 during liver preservation is associated with early allograft dysfunction and graft survival after transplantation[J]. Liver Transpl, 2017, 23(7): 946-956. DOI: 10.1002/lt.24766.
|
[61] |
SHEN ZY, WU B, LIU T, et al. Immunomodulatory effects of bone marrow mesenchymal stem cells overexpressing heme oxygenase-1: protective effects on acute rejection following reduced-size liver transplantation in a rat model[J]. Cell Immunol, 2017, 313: 10-24. DOI: 10.1016/j.cellimm.2016.12.006.
|
[62] |
XIE Y, WU Y, XIN K, et al. Delayed donor bone marrow infusion induces liver transplant tolerance[J]. Transplantation, 2017, 101(5): 1056-1066. DOI: 10.1097/tp.0000000000001684.
|
[63] |
SENDRA GISBERT L, MIGUEL MATAS A, SABATER ORTÍ L, et al. Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation[J]. Liver Transpl, 2017, 23(1): 50-62. DOI: 10.1002/lt.24667.
|